AR031032A1 - Uso de la tolterodina en el tratamiento del asma - Google Patents

Uso de la tolterodina en el tratamiento del asma

Info

Publication number
AR031032A1
AR031032A1 ARP010104944A ARP010104944A AR031032A1 AR 031032 A1 AR031032 A1 AR 031032A1 AR P010104944 A ARP010104944 A AR P010104944A AR P010104944 A ARP010104944 A AR P010104944A AR 031032 A1 AR031032 A1 AR 031032A1
Authority
AR
Argentina
Prior art keywords
asthma
tolterodine
treatment
copd
group
Prior art date
Application number
ARP010104944A
Other languages
English (en)
Original Assignee
Upjohn Co
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co, Pharmacia Ab filed Critical Upjohn Co
Publication of AR031032A1 publication Critical patent/AR031032A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicinal Preparation (AREA)

Abstract

Es un método para tratar un mamífero, seleccionado del grupo integrado por seres humanos y caballos, que sufre de asma, EPOC o rinitis alérgica y requiere dicho tratamiento, mediante la inhalacion de una dosis eficaz contra el asma, la EPOC o la rinitis alérgica, respectivamente, de un compuesto seleccionado del grupo integrado por la tolterodina, formula 1; la hidroxitolterodina y el 1-fenilciclopentanocarboxilato de 2-(diisopropilamino) etilo y sus sales farmacéuticamente aceptables.
ARP010104944A 2000-10-24 2001-10-22 Uso de la tolterodina en el tratamiento del asma AR031032A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24289900P 2000-10-24 2000-10-24
US28312001P 2001-04-11 2001-04-11
US31421801P 2001-08-22 2001-08-22

Publications (1)

Publication Number Publication Date
AR031032A1 true AR031032A1 (es) 2003-09-03

Family

ID=27399612

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010104944A AR031032A1 (es) 2000-10-24 2001-10-22 Uso de la tolterodina en el tratamiento del asma

Country Status (9)

Country Link
US (1) US6538035B2 (es)
EP (1) EP1330241A2 (es)
JP (1) JP2004513099A (es)
AR (1) AR031032A1 (es)
AU (1) AU2002212962A1 (es)
CA (1) CA2422901A1 (es)
MX (1) MXPA03003592A (es)
PE (1) PE20020547A1 (es)
WO (1) WO2002034245A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
CA2464223C (en) * 2001-10-26 2009-05-26 Pharmacia & Upjohn Company Quarternary ammonium compounds and their use as antimuscarinic agents
BR0206300A (pt) * 2001-11-05 2008-04-08 Upjohn Co composição farmacêutica para tratar distúrbio urinário em um mamìfero e uso
PL372395A1 (en) * 2002-02-19 2005-07-25 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence
US7005449B2 (en) 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
MXPA05011059A (es) * 2003-04-15 2005-12-12 Pharmacia & Upjohn Co Llc Compuestos de amonio cuaternario y su uso como agentes antimuscarinicos.
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法
US7629358B2 (en) * 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
ES2268987B1 (es) 2005-08-05 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de 3,3-difenilpropilaminas.
AU2007228511A1 (en) 2006-03-20 2007-09-27 Pfizer Limited Amine derivatives
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
CA2699463A1 (en) * 2007-09-14 2009-03-19 Pfizer Limited Novel compounds active as muscarinic receptor antagonists
KR101188333B1 (ko) 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
CN110372571B (zh) * 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
SK4699A3 (en) 1996-07-29 2000-04-10 Pharmacia & Upjohn Ab Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재

Also Published As

Publication number Publication date
PE20020547A1 (es) 2002-06-12
CA2422901A1 (en) 2002-05-02
EP1330241A2 (en) 2003-07-30
MXPA03003592A (es) 2003-06-19
US20020161054A1 (en) 2002-10-31
JP2004513099A (ja) 2004-04-30
US6538035B2 (en) 2003-03-25
WO2002034245A2 (en) 2002-05-02
AU2002212962A1 (en) 2002-05-06

Similar Documents

Publication Publication Date Title
AR031032A1 (es) Uso de la tolterodina en el tratamiento del asma
CL2020003329A1 (es) Moléculas de ácido nucleico para la reducción de arnm de papd5 o papd7 para tratar la infección por hepatitis b (divisional solicitud no. 3561-2018)
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
UY28041A1 (es) Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial.
AR025111A1 (es) Metodos y composiciones para tratar trastornos de ansiedad generalizada
PA8510801A1 (es) "tratamiento de la enfermedad neurodegenerativa"
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
AR082825A2 (es) Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios
SV2003000633A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7
NI201500031A (es) Métodos para tratar la enfermedad de alzheimer y composiciones farmacéuticas de los mismos.
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
ECSP055689A (es) Inhibidor potente de la serina proteasa del vhc
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
BR0208192A (pt) Derivados espirotricìclicos e seu uso como inibidores da fosfodiesterase-7.
CO2022013777A2 (es) Uso de agentes para el tratamiento de condiciones respiratorias
AR056566A1 (es) Vacunas y procedimientos para tratar la gripe canina
UY27991A1 (es) Derivados de pirrolidona domo inhibidores de maob
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
DOP2003000585A (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
AR058298A1 (es) Composicion veterinaria
BRPI0411324A (pt) composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
AR029588A1 (es) Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure